{"symbol": "SNY", "name": "Sanofi", "next_earnings_utc": 1595584800, "next_earnings_period_start_date_utc": 1585612800, "next_earnings_period_end_date_utc": 1593475200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": 9496956281.128942, "next_earnings_eps_num_analysts": null, "next_earnings_eps_consensus": 0.63, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 8, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 1, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "sanofi.com", "year_founded": 1994, "street_address": "54, Rue La Bo\u00c3\u00a9tie", "city": "Paris", "state": null, "zipcode": "75008", "country": "France", "phone_number": "33 1 53 77 40 00", "short_description": "Sanofi provides therapeutic solutions worldwide.", "long_description": "Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; and GlaxoSmithKline Plc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 121656598845, "total_enterprise": 140037825961, "number_of_employees": 100409, "outstanding_shares": 1252702988, "eps": 2.95224487546837, "diluted_eps": 2.93264051135111, "earnings_from_cont_operations": 3841745647, "gross_profit": 28668723826, "cash": 10515759312, "total_debt": 28581661891, "total_revenue": 42135772537, "cash_from_operations": 8686483455, "net_income": 3694070972, "ebitda": 11615605025, "year_low_stock_price": 37.62, "year_high_stock_price": 51.84, "seekingalpha_follower_count": 43084, "image_url": "https://raw.githubusercontent.com/earnbros/earnbros.github.io/master/api/images/companies/SNY.png"}